Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice.

Fletcher SV, Jones MG, Renzoni EA, Parfrey H, Hoyles RK, Spinks K, Kokosi M, Kwok A, Warburton C, Titmuss V, Thillai M, Simler N, Maher TM, Brereton CJ, Chua F, Wells AU, Richeldi L, Spencer LG.

ERJ Open Res. 2018 Oct 19;4(4). pii: 00049-2018. doi: 10.1183/23120541.00049-2018. eCollection 2018 Oct.

2.

Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis.

Goh NS, Hoyles RK, Denton CP, Hansell DM, Renzoni EA, Maher TM, Nicholson AG, Wells AU.

Arthritis Rheumatol. 2017 Aug;69(8):1670-1678. doi: 10.1002/art.40130. Epub 2017 Jul 18.

3.

British Lung Foundation/United Kingdom Primary Immunodeficiency Network Consensus Statement on the Definition, Diagnosis, and Management of Granulomatous-Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency Disorders.

Hurst JR, Verma N, Lowe D, Baxendale HE, Jolles S, Kelleher P, Longhurst HJ, Patel SY, Renzoni EA, Sander CR, Avery GR, Babar JL, Buckland MS, Burns S, Egner W, Gompels MM, Gordins P, Haddock JA, Hart SP, Hayman GR, Herriot R, Hoyles RK, Huissoon AP, Jacob J, Nicholson AG, Rassl DM, Sargur RB, Savic S, Seneviratne SL, Sheaff M, Vaitla PM, Walters GI, Whitehouse JL, Wright PA, Condliffe AM.

J Allergy Clin Immunol Pract. 2017 Jul - Aug;5(4):938-945. doi: 10.1016/j.jaip.2017.01.021. Epub 2017 Mar 25. Review.

4.

Therapeutic advances in idiopathic pulmonary fibrosis.

Fraser E, Hoyles RK.

Clin Med (Lond). 2016 Feb;16(1):42-51. doi: 10.7861/clinmedicine.16-1-42. Review.

5.

Development of a Consensus Statement for the Definition, Diagnosis, and Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis Using the Delphi Technique.

Maher TM, Whyte MK, Hoyles RK, Parfrey H, Ochiai Y, Mathieson N, Turnbull A, Williamson N, Bennett BM.

Adv Ther. 2015 Oct;32(10):929-43. doi: 10.1007/s12325-015-0249-6. Epub 2015 Oct 23.

6.

Efficacy of tocilizumab for interstitial lung disease in an undifferentiated autoinflammatory disorder partially responsive to anakinra.

Keidel SM, Hoyles RK, Wilkinson NM.

Rheumatology (Oxford). 2014 Mar;53(3):573-4. doi: 10.1093/rheumatology/ket211. Epub 2013 Aug 22. No abstract available.

PMID:
23970544
7.

Increased epithelial permeability in pulmonary fibrosis in relation to disease progression.

Goh NS, Desai SR, Anagnostopoulos C, Hansell DM, Hoyles RK, Sato H, Denton CP, Black CM, du Bois RM, Wells AU.

Eur Respir J. 2011 Jul;38(1):184-90. doi: 10.1183/09031936.00010910. Epub 2010 Oct 28.

8.

An essential role for resident fibroblasts in experimental lung fibrosis is defined by lineage-specific deletion of high-affinity type II transforming growth factor β receptor.

Hoyles RK, Derrett-Smith EC, Khan K, Shiwen X, Howat SL, Wells AU, Abraham DJ, Denton CP.

Am J Respir Crit Care Med. 2011 Jan 15;183(2):249-61. doi: 10.1164/rccm.201002-0279OC. Epub 2010 Aug 13.

PMID:
20709822
9.

Pivotal role of connective tissue growth factor in lung fibrosis: MAPK-dependent transcriptional activation of type I collagen.

Ponticos M, Holmes AM, Shi-wen X, Leoni P, Khan K, Rajkumar VS, Hoyles RK, Bou-Gharios G, Black CM, Denton CP, Abraham DJ, Leask A, Lindahl GE.

Arthritis Rheum. 2009 Jul;60(7):2142-55. doi: 10.1002/art.24620.

10.

Inducible lineage-specific deletion of TbetaRII in fibroblasts defines a pivotal regulatory role during adult skin wound healing.

Denton CP, Khan K, Hoyles RK, Shiwen X, Leoni P, Chen Y, Eastwood M, Abraham DJ.

J Invest Dermatol. 2009 Jan;129(1):194-204. doi: 10.1038/jid.2008.171. Epub 2008 Jun 19.

11.

Fibroblast-specific perturbation of transforming growth factor beta signaling provides insight into potential pathogenic mechanisms of scleroderma-associated lung fibrosis: exaggerated response to alveolar epithelial injury in a novel mouse model.

Hoyles RK, Khan K, Shiwen X, Howat SL, Lindahl GE, Leoni P, du Bois RM, Wells AU, Black CM, Abraham DJ, Denton CP.

Arthritis Rheum. 2008 Apr;58(4):1175-88. doi: 10.1002/art.23379. Erratum in: Arthritis Rheum. 2015 Oct;67(10):2741.

12.

A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.

Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, Roberts C, Desai S, Herrick AL, McHugh NJ, Foley NM, Pearson SB, Emery P, Veale DJ, Denton CP, Wells AU, Black CM, du Bois RM.

Arthritis Rheum. 2006 Dec;54(12):3962-70.

Supplemental Content

Loading ...
Support Center